In a recent announcement, the Food and Drug Administration (FDA) has urged healthcare professionals to promptly report any adverse reactions linked to the use of anaesthesia. This directive comes in response to mounting concerns raised by healthcare practitioners regarding the efficacy of certain anaesthesia products. Particularly, those containing bupivacaine, a potent local anaesthetic, have drawn significant attention. The FDA’s stance aims to address these concerns and ensure patient safety in anaesthesia administration.